Prior notification of a concentration

(Case M.9711 – Alliance Healthcare Deutschland/Gehe Pharma Handel)

(Text with EEA relevance)

(2020/C 235/05)

1. On 10 July 2020, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1].

This notification concerns the following undertakings:

— Alliance Healthcare Deutschland AG (Germany), controlled by Wallgreens Boots Alliance, Inc. (USA),

— Gehe Pharma Handel GmbH (Germany), controlled by McKesson Corporation (USA).

Alliance acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Gehe.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— Alliance is a full-line pharmaceutical wholesaler, active mainly in Germany,

— Gehe is a full-line pharmaceutical wholesaler, active mainly in Germany.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9711 – Alliance Healthcare Deutschland/Gehe Pharma Handel

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

---

[1] OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').